Provided by RMEI Medical Education, LLC      

Target Audience

Pulmonology, infectious diseases, primary care, and radiology clinicians managing patients with NCFBE

Learning Objectives

Upon completion of this activity, participants should be better able to:

• Identify the impact of non-cystic fibrosis bronchiectasis (NCFBE) and its exacerbations on patient quality of life
• Utilize clinical practice guidelines for NCFBE diagnosis
• Examine emerging treatments targeting the underlying immune-mediated pathophysiologic processes of NCFBE
• Integrate the unique roles and responsibilities of the interprofessional care team when diagnosing and treating patients with NCFBE

Faculty

Mark L. Metersky, MD, FCCP, is a Professor of Medicine at the University of Connecticut School of Medicine where he serves as the Associate Chief of Service for the Department of Medicine, Chief of the Division of Pulmonary, Critical Care and Sleep Medicine, and Director of UCONN Center for Bronchiectasis Care. Dr Metersky received his medical degree from New York University School of Medicine. He then completed an internship and residency in internal medicine at Boston City Hospital and then a fellowship in pulmonary and critical medicine at the University of California, San Diego Medical Center. Dr Metersky is board certified in internal medicine, critical care medicine, and pulmonary disease.

Dr Metersky has a long-standing interest in pulmonary infections, including pneumonia and bronchiectasis and has published over 150 papers and has presented extensively on these subjects. He serves as an ad hoc reviewer for over 20 journals and is an Assistant Associate editor of CHEST. He was the American Thoracic Society (ATS) co-chair of the writing panel for the “Management of Adults with Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society” and was an author of the 2019 ATS/IDSA Community-Acquired Pneumonia Guidelines.

Dr Metersky has served in multiple leadership positions for the ATS Pulmonary Infections and Tuberculosis Assembly, including Assembly Program Chair, Chair of the Nominating Committee, and member of the Planning Committee and Acute Pneumonia Working Group. He has also published extensively on quality and patient safety and serves as the chair of the ATS Quality Improvement and Implementation Committee.

Margaret M. Johnson, MD, is a consultant in the Division of Pulmonary Medicine at Mayo Clinic in Jacksonville, FL and a Professor of Medicine. Additionally, she serves as Dean of the Florida campus of the Mayo Clinic College of Medicine and Biomedical Sciences. Dr Johnson received her medical degree from Jefferson Medical College at Thomas Jefferson University in Philadelphia, PA. She completed her residency in internal medicine at Thomas Jefferson University and completed her fellowship in pulmonary and critical care at Wake Forest University/Bowman Gray School of Medicine in Winston-Salem, NC. Dr Johnson is board certified in critical care medicine and pulmonary disease.

Dr Johnson has been active in clinical pulmonary and critical care medicine, basic and clinical research, education, and administrative leadership roles. Her clinic focus includes bronchiectasis, non-tuberculous mycobacterial lung disease, lung cancer screening, and cystic fibrosis. She developed and is the director of the Adult Cystic Fibrosis Program at Mayo Clinic and is active in clinical trials.

Central to Dr Johnson’s career has been medical education across the spectrum of learners from medical students to professional colleagues. She has delivered over 200 CME lectures nationally and internationally and has been recognized as the Distinguished Educator at Mayo Clinic in Florida, as well as other education awards.

Molly Mailes, MSN, RN, MEDSURG-BC, is the nurse program coordinator of the Adult Cystic Fibrosis program at the Mayo Clinic in Jacksonville, FL. Nurse Mailes works alongside Dr Margaret Johnson, as well as the other cystic fibrosis team. In addition to her role as the program coordinator, Nurse Mailes works with Dr Johnson’s patients with non-cystic fibrosis bronchiectasis and non-tuberculosis mycobacterium. As part of their thorough care at Mayo Clinic, she provides airway clearance therapy education to all of these patient groups. Nurse Mailes has a Master of Science degree in Nursing Leadership and is a certified medical-surgical nurse through the American Nursing Credentialing Center. She has many years of nursing experience in both inpatient and outpatient nursing care.

Nurse Mailes’ focus is on quality improvement projects, in an effort to provide the best patient care. She has been nominated for the Daisy Award 8 times and for the Florence Nightingale Luminary Award. She was awarded a Nurse Exemplar-Problem Solver Award and is always recognized for her hard work and attention to detail.

Nurse Mailes has created and presented 4 different posters. Three of the 4 posters were accepted and presented at National conferences and one was presented at the Florida Value Symposium at the Mayo Clinic in Florida. She was also a co-author this summer for a chapter in the book Modern Nutrition in Health and Disease, 12^th edition.

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Margaret M. Johnson, MD, has no relevant financial relationship(s) with ineligible companies to disclose.

Molly Mailes, MSN, RN, MEDSURG-BC, has no relevant financial relationship(s) with ineligible companies to disclose.

Mark L. Metersky, MD, has relevant financial relationships with Boehringer Ingelheim, Insmed, Tactile Medical, Zambon (Consultant); AN2, Renovion (Other: Data Safety Monitoring Board); Insmed (Researcher).

Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers

RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours.

Interprofessional Continuing Education

This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation and Request for Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at accreditation@rmei.com.

Users must:

• Read the learning objectives and faculty disclosures
• Participate in the activity
• Complete the activity evaluation and attest to credit.

There is no fee to participate.

Statement of Commercial Support

This activity is supported by an educational grant from Insmed

Resources

• Slides
• Clinical Trials Investigating New Agents for the Treatment of NCFBE

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.